Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | CASP2 | P42575 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.31 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.30 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.30 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3074874 | 0.81 | CA2 (0.44) | CA2CA1ALDH1A1MEN1KMT2A | |
| SCHEMBL385127 | 0.80 | ECE1 (0.58) | ECE1KMT2AGLRA1SLC6A9OR51E2 | |
| SCHEMBL2200631 | 0.80 | CA2 (0.38) | CA2CA1ECE1ALDH1A1MEN1 | |
| SCHEMBL28969880 | 0.77 | CA1 (0.39) | CA2CA1ECE1ALDH1A1MEN1 | |
| SCHEMBL16853212 | 0.76 | ALDH1A1 (0.55) | CA2CA1ALDH1A1MEN1KMT2A | |
| SCHEMBL152135 | 0.76 | — | — | |
| SCHEMBL12660515 | 0.76 | MEN1 (0.48) | CA2CA1ALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL25330006 | 0.75 | CA1 (0.38) | CA2CA1ECE1ALDH1A1MEN1 | |
| SCHEMBL18404145 | 0.75 | LMNA (0.52) | CA2ALDH1A1MEN1KMT2ATSHR | |
| Oxalic Acid SCHEMBL28780170 | 0.75 | ECE1 (0.52) | CA2CA1ECE1KMT2AGLRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135502-B1 | Colchinol derivatives as vascular damaging agents | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2006-11-14 | — | — | US | disclosed |
| US-20060128633-A1 | Colchinol derivatives as vascular damaging agents | ANGIOGENE PHARMACEUTICALS LTD. | 2006-06-15 | — | — | US | disclosed |
| EP-1140745-B1 | COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS | ANGIOGENE PHARM LTD (GB) | 2003-10-22 | — | — | EP | disclosed |
| EP-1140745-A1 | COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS | Angiogene Pharmaceuticals Ltd (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040529-A1 | COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128633-A1 | Colchinol derivatives as vascular damaging agents | NR1H3, NR1H2, NR1H4 | CA2 2559/4885CA1 1906/4885ECE1 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.